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ABSTRACT
Soybean (Glycine max) is one of the most cultivated crops in the world providing
the population with large amounts of protein and oil. In addition to its nutritional
composition, soybean also contains biologically active compounds with potential
health-promoting properties. The presence of these bioactives may be
responsible for the lower incidence of chronic diseases in populations that
consume a significant portion of soybeans in their diet. One group of soybeanderived bioactives are bioactive peptides and proteins including lunasin,
Bowman-Birk inhibitor (BBI) and Kunitz-type trypsin inhibitor (KTI). The overall
objective of this research was to develop a method of preparing lunasin-enriched
material and evaluate the ability of lunasin-enriched material to inhibit activation
of the inflammasomes in vitro. Lunasin-enriched materials were prepared using
calcium chloride and pH precipitation methods and compared with two
commercially-available lunasin-enriched products. The stability of lunasin against
pepsin-pancreatin hydrolysis was evaluated in these materials and the effect of
BBI and KTI concentrations were analyzed. Lunasin concentrations ranged from
8.5 to 71.0 µg [microgram]/g pre-hydrolysis and 4.0 to 13.2 µg/g after hydrolysis.
In all products tested, lunasin concentration after pepsin-pancreatin hydrolysis
(PPH) significantly correlated with BBI and KTI concentrations. One lunasinenriched preparation was evaluated for its ability to modify activation of the
inflammasomes in vitro using THP-1 human macrophages. Aberrant activation of
the inflammasomes is associated with development of human diseases such as
v

cancer, diabetes and inflammatory bowel diseases. The activation of the
inflammasomes in THP-1 human macrophages was accomplished by priming
with lipopolysaccharide followed by adenosine triphosphate. Lunasin-enriched
material was added during the priming step at concentrations ranging from
0.0625 to 0.25 mg/mL. Addition of lunasin-enriched preparation led to reduction
of intracellular reactive oxygen species (ROS) which correlated with reduction in
the amount of pro-inflammatory cytokines interleukin-1β(beta) and interleukin-18.
These results indicate that ROSs play an integral role in lunasin’s ability to inhibit
inflammation and inflammasomes’ activation. This research is the first to report
on the role of Kunitz-type trypsin inhibitor on the stability of lunasin against PPH
and potential of lunasin-enriched preparations as chemopreventive agent against
diseases associated with aberrant activation of the inflammasomes.
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CHAPTER I
INTRODUCTION
Soy is commonly consumed throughout the world, especially in Asian
countries, because it contains high amounts of protein and many essential amino
acids that are not commonly found in other plants (Michelfelder, 2009). Soy was
used as far back as 9000 B.C in China and 7000 B.C in Japan (Lee et al.,,
2011)as a staple food. Soybeans are still an important part of Asian cuisine with
multiple food products produced such as soymilk, soy sauce, tempeh, and tofu
(Singh et al., 2008). Soy is used in Asian cultures because it contains large
amounts of protein so it is a suitable meat substitute for people with vegetarian
diets. In modern times, soybeans have become the most widely used legume
because of its use in food and oil production (Singh et al., 2008). In 2015, the
United States produced a total of 3.93 billion bushels of soy (USDA National
Agricultural Statistics Service, 2016), showing its importance as a crop. Although
the United States produces large amounts of soy, it is not used in human food
products as much as it is in Asia.
In countries that have higher rates of soy consumption (especially Asia), it
has been shown that there are decreased risks for certain types of diseases such
as cardiovascular disease, obesity and cancer (Wu et al., 1998). For instance,
Asian women have reduced risks of breast and other types of cancers compared
to women in western countries due to their increased intake of soy (Wu et al.,
2008). This has prompted studies into the composition of soy to understand this
1

observation. The recent data suggest that bioactive compounds in soy are
responsible for the reduced risks of certain cancers. However, the exact reasons
of how bioactive compounds have these protective effects is largely unknown.
One group of bioactive compounds are peptides which can be either
naturally occurring or produced by enzymatic hydrolysis and fermentation. Foodderived bioactive peptides in addition to their nutritional value exert a
physiological effect in the body acting as potential metabolism modulators and
regulatory compounds (Shahidi & Zhong, 2008). Some of the bioactive peptides
found in soy include Bowman-Birk Inhibitor (BBI), Kunitz-Trypsin Inhibitor (KTI),
soymetides, soymorphins, and lunasin (Wang & Gonzalez De Mejia, 2005).
Previous studies have shown the chemopreventive property of these bioactive
peptides associated with their anti-inflammatory effects. BBI inhibited
autoimmune inflammation and neuronal loss in a mouse model of multiple
sclerosis (Touil et al., 2008) while KTI suppressed lipopolysaccharide-induced
inflammation by reducing expressions of pro-inflammatory cytokines tumor
necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and IL-6. In addition, lunasin
attenuated obesity related inflammation by reducing production of proinflammatory cytokines monocyte chemoattractant protein-1 and IL-1β in a coculture model of RAW 264.7 macrophages and 3T3-L1 adipocytes (Hsieh et al.,
2017).
Cytokines are small secreted proteins released by immune cells in
response to a variety of stimuli and have diverse effects on the interactions of
2

cells in the body(Tilg et al., 2016). The IL-1 family has been implicated in different
pathogenesis associated with their pro-inflammatory effects such as Parkinson’s
disease (Mao et al., 2017), multiple sclerosis (Barclay & Shinohara, 2017) and
inflammatory bowel diseases (Peyrin-Biroulet, Lémann, 2011; Ruffolo et al.,
2010). The release of IL-1 family of cytokines such as IL-1β and IL-18 is
controlled by activation of macromolecular protein complex called the
inflammasomes(Domiciano et al., 2017). Inflammasomes are multiprotein
complexes that are formed within macrophages after danger-associated
molecular patterns (DAMPs) and pathogen-associated molecular patterns
(PAMPs) stimulation which induce the production of IL-1β and IL18 as well as the
inflammatory caspase family subtypes (Lu & Wu, 2015). Chronic inflammation
by overexpression of the inflammasomes and the associated pro-inflammatory
cytokines have been linked to multiple conditions, such as metabolic disorders
(atherosclerosis, Type II diabetes) as well as mucosal immune responses that
can lead to inflammatory bowel syndrome (IBS) (Strowig et al., 2012).
To date there is a lack of information on how soybean-based products, such
as lunasin-enriched material, can modify inflammasomes activation. If soybeanbased products, especially lunasin-enriched materials, can inhibit the
inflammasome, then this could lead to more studies to determine if lunasin could
be a viable chemopreventive option in diseases associated with chronic
inflammation, as well as for other potential uses. If future studies are able to
conclude that lunasin and other soy-based products are able to be used as
3

treatments, then a proposal to the FDA to grant this health promoting claim would
be the next step.

Hypothesis and Objectives
Objectives
The overall objectives are to develop a method of preparing lunasin-enriched
material and evaluate the ability of lunasin-enriched material to inhibit activation
of the inflammasomes in vitro.
Central Hypothesis
Lunasin-enriched material prepared from defatted soybean flour can inhibit
activation of the inflammasomes by reducing reactive oxygen species.
Aims
Aim 1. To develop a method of preparing lunasin-enriched material and
determine the effect of soybean protease inhibitors in the stability of
lunasin against pepsin-pancreatin hydrolysis
Hypothesis: The concentrations of soybean protease inhibitors BBI and KTI will
correlate to the stability of lunasin against pepsin-pancreatin hydrolysis in
different lunasin-enriched preparations.
1.1 To develop a method of producing lunasin-enriched preparations using
CaCl2 and pH precipitation methods;
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1.2 To compare the concentrations of lunasin, BBI and KTI among
lunasin-enriched preparations and two commercially available lunasinenriched products;
1.3 To determine the effect of BBI and KTI on the stability of lunasin
against pepsin-pancreatin hydrolysis; and
1.4 To measure the antioxidant activities of lunasin-enriched preparations
and their pepsin-pancreatin hydrolysis products.
Aim 2. To evaluate the potential of lunasin-enriched material to modify
activation of the inflammasomes in THP-1 human macrophages in vitro.
Hypothesis: Lunasin-enriched material can inhibit activation of the
inflammasomes in THP-1 human macrophages in vitro
2.1 To investigate the effect of lunasin-enriched material in the production
of IL-1β and IL-18 in THP-1 human macrophages primed and activated by
lipopolysaccharide and adenosine-triphosphate, respectively;
2.2 To determine the mechanism of inactivation of the inflammasomes by
the lunasin-enriched material in vitro; and
2.3 To determine the effect of pepsin-pancreatin hydrolysis on the ability
of lunasin-enriched material to inhibit activation of the inflammasomes in
vitro.
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CHAPTER II
LITERATURE REVIEW
Soybeans and soybean proteins

Soybeans (Glycine max) are an important legume because they contain large
amounts of protein, and they were used for ~68% of global protein meal
production in 2006 (Krishnan et al., 2009). Soybeans contain approximately 40%
protein per seed (USDA National Agricultural Statistics Service, 2016) and the
majority of these proteins are one of two storage proteins, the 11s glycinin and 7s
ß-conglycinin families, which make up 40 and 30% of these proteins, respectively
(Utsumi et al., 2002). Another study was able to identify 80 unique proteins
within the glycinin and ß-conglycinin family, falling under four distinct categories
based on solubility (Natarajan et al., 2006). The categories are water-soluble
albumins, salt-soluble globulins, weak acid/base-soluble glutelins, and alcoholsoluble prolamins (Ferreira et al., 1999). Other proteins found within soybean
include γ-conglycinin, lipoxygenase, ß-amylase, basic 7s globulin, agglutinin, and
2s albumins from the 2s seed storage protein family (El-moneim et al., 2011).
Proteins are classified under sedimentation coefficients, or Svedburg units, such
as 7s and 11s, which uses the weight and shape of the protein to determine the
coefficient (Smith, 1988). Albumins are classified in the globular protein family
due to their shape, but differ categorically from globulins because they are
soluble in water (Masuelli, 2013), whereas globulins are soluble with low salt
concentrations (Sirison et al., 2017).
9

Bioactive proteins and peptides from soybean

Glycinin and ß-conglycinin have been found to contain proteins that induce
allergic reactions (Holzhauser et al., 2009), but other peptide sections contained
within both of these proteins have bioactive properties, such as improved glucose
and lipid metabolism from soymorphins (Yamada et al., 2012), and reduced
cholesterol absorption from soystatins (Nagaoka et al., 2010). There are other
bioactive peptides found in soy that come from sources other than the glycinin
and ß-conglycinin, such as lunasin from 2s albumins, (Galbas et al., 2013) and
bioactive proteins such as protease inhibitors (Gillman et al., 2015).

Lunasin. Lunasin is a peptide naturally found in soy and other grains such as
barley and quinoa (Ren & Zhu, 2017). Soy is the most commonly used source
for the extraction of lunasin, because it contains large amounts of protein,
comprising approximately 41% protein, 90% of which are globulins and the
remaining 10% are albumins (Singh et al., 2008). Lunasin is a 2S albumin with a
43 amino acid sequence:
SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGDDDDDDDDD (CruzHuerta et al., 2015). Because there are very small amounts of lunasin in soy,
compared to other proteins, new methods have been implemented in order to
increase the yields and purity of lunasin directly extracted from soy. The newest
method uses 100 grams of de-fatted soy flour in one liter of an aqueous 30%
10

ethanol solution to extract proteins from the soy flour, and it is then centrifuged
and the supernatant fluid is precipitated with CaCl2 and further centrifuged before
being lyophilized (Krishnan & Wang, 2015).
Several studies have shown the chemopreventive effect of lunasin extracted from
soybean using different in vitro and in vivo experiments. Oral administration of
lunasin showed that lunasin was able to spread throughout the body and reach
areas that are most commonly associated with cancer (i.e. colon, breast, lung),
meaning that it is possible to reach a target site through oral administration only
(Hsieh et al., 2010). Another study showed that lunasin was found in the blood
plasma of men after ingesting soy (Dia et al., 2009) indicating that lunasin is able
to be absorbed and transported throughout the body. In the study that used
intravenous and intraperitoneal administration, it was shown that lunasin
administered at 30 mg/kg body weight in mouse xenograft model reduced tumor
weight of A375 melanoma cell line, with the intravenous injection reducing 35%
of total weight and the intraperitoneal injection reducing 46% of the total weight
(Shidal et al., 2016).
Though oral administration of lunasin is the best route for use as a
chemopreventive agent, lunasin might become digested and proteolyzed if not
protected by a protease inhibitor such as the Bowman-Birk protease inhibitor
(BBI). If there is no protease inhibitor, then pepsin hydrolyzed up to 97% of the
lunasin, which was the result when the gastric process was simulated in vitro
(Cruz-Huerta et al., 2015). Once the peptide has been absorbed into the blood
11

stream, it will reach the target cells and eventually collect in the liver and kidneys
(Galbas et al., 2013), but there have been studies that indicate it does not affect
the functionality of the liver or kidney cells (Al-Rayyan et al., 2014).
There are many health benefits for lunasin, ranging from anti-cancer(Cruz-Huerta
et al., 2015), anti-obesity (Liu et al. 2014), prevention from cardiovascular
disease (Cam & de Mejia, 2012), and anti-inflammatory properties (Dia et al.
2009). The majority of recent studies have focused on the use of lunasin as an
anti-tumor and cancer treatment through various means, with the most prominent
being the arginine-glycine-aspartic acid (RGD) motif found along the 32nd-34th
amino acids in the sequence (Setrerrahmane et al., 2014). Peptides that contain
the RGD motif have been found to suppress inflammation and promote apoptosis
in different cancer cell lines(Dia & de Mejia, 2010). RGD motif containing
peptides are able to cause apoptosis through the activation of pro-caspase-3, a
protein that contains an aspartate-aspartate-methionine site that binds with the
RGD, which triggers integrin activation and causes the pro-caspase-3 to activate,
and induces apoptosis among cells by allowing caspase-3 to penetrate the cell
walls and activate the enzymatic activity of the protein (Buckley et al., 1999).
Lunasin is also able to amplify the effects of other treatments such as amplifying
the amount of Interferon Gamma (IFN-γ) produced by natural killer (NK) cells in
post-transplant lymphoma patients, where IFN-γ is an interferon used for antitumor immunity by enhancing tumor immunogenicity for antigen presentation,
producing apoptosis in tumor cells, promoting T helper 1 cell differentiation, and
12

enhancing cytotoxicity of CD8+ cytotoxic T lymphocytes (Chang et al., 2014).
Once the IFN-γ is able to be produced again, the immune system will be able to
function on an improved level. In addition, lunasin has been shown to be antiinflammatory through the inhibition of production of inflammatory responses
including nitric oxide, prostaglandins, and cytokines(de Mejia & Dia, 2009). For
instance, lunasin was able to allergic airway inflammation important in asthma
therapy and allergy immunotherapy (Yang et al., 2015) and lunasin showed
potent radical scavenging activities in intestinal CaCo-2 cells indicating its
promising activity to preserve intestinal mucosal integrity against oxidative
damage (Garcia-Nebot et al., 2014).

Protease inhibitors. Protease inhibitors are molecules (typically proteins) that
are able to inhibit proteolytic enzymes. Because there are so many different
types of protease inhibitors, they have been broken down into “families” and
“clans” to help in differentiating them through means such as inhibitory sites and
proteases inhibited (Rawlings et al., 2004). Proteases are divided into seven
different families and are all based on the catalytic residues, the site that either
binds to a peptide bond or utilizes an acid to hydrolyze the peptide bond (Oda,
2012). Six families of proteases use different amino acids as the catalytic triad in
the active site, with the seventh being a metalloprotease. The largest protease
family is the serine protease family, which accounts for approximately one third of
proteases (Di Cera, 2009). Two proteases that belong to a subfamily of the
13

serine protease family are chymotrypsin-like which cleaves the hydrophobic
amino acids, and trypsin like which cleaves after arginine and lysine (Rawlings et
al. 2016). Two protease inhibitors found in soy come from two different families,
the BBI family and the Kunitz-type Trypsin Inhibitor (KTI) family. The BBI found
in soy has two binding sites, one for trypsin and one for chymotrypsin. It is able
to inhibit chymotrypsin and trypsin by the standard, or Laskowski method. The
Laskowski method is described as an inhibitor having a specific peptide bond
corresponding to the protease catalytic site, thus binding with it and at a neutral
pH does not completely hydrolyze, instead forming an equilibrium between
hydrolyzed and non-hydrolyzed peptide bonds and stable enzyme-substrate
complex (Laskowski & Kato, 1980; Rawlings et al., 2016). BBI is able to inhibit
one trypsin molecule and one chymotrypsin molecule per molecule of BBI using
a lysine-leucine peptide bond, with lysine binding to trypsin and leucine binding to
chymotrypsin (Rawlings et al., 2016). The KTI found in soy has a high affinity for
trypsin, and is responsible for approximately 76% of the trypsin inhibition (Chen
et al., 2014). KTI also uses the Laskowski method, but uses an arginineisoleucine peptide bond to strongly bind to trypsin (Wasmuth & Lima, 2016), as
well as protruding loop that is inserted into the active site of enzymes (Azarkan et
al., 2011). Since these protease inhibitors are found in soy, they can be
concentrated along with lunasin to potentially prevent its digestion upon oral
administration.

14

Bowman-Birk Inhibitor. The BBI is found within soy and other seeds of
legumes. The species found in soybeans has110 amino acids with the following
sequence:
MVVLKVCLVLLFLVGGTTSANLRLSKLGLLMKSDHQHSNDDESSKPCCDQCAC
TKSNPPQCRCSDMRLNSCHSACKSCICALSYPAQCFCVDITDFCYEPCKPSED
DKEN(Wasmuth & Lima, 2016). Each source of BBI contains protease inhibitors
that can differ slightly (as is the case in horse gram and soy which differs only by
a few amino acids) or greatly (as is the case of eudicots BBI which are typically 8
kDa with two proteolytic sites versus monocots BBI is either 8 kDa with one
proteolytic site, or 16 kDa with two proteolytic sites) (Prakash et al., 1996). This
specific family of protease inhibitors are a cysteine-rich group, and characterized
by a lower molecular weight (8 kDa for soy-based) and large amounts of disulfide
bonds, 7 of which is present in soybean BBI (Odani et al., 1973). The purpose of
a protease inhibitor is to protect against enzymes that proteolyze proteins, and
BBI protects against the proteolytic enzymes trypsin and chymotrypsin (Odani et
al., 1973). The trypsin and chymotrypsin inhibitory properties are due to multiple
disulfide bonds creating two inhibition sites (Werner & Wemmer, 1992). In soy
processing, the protease inhibitors found are considered to be disadvantageous
because protein digestibility could be affected (Lu et al., 2015), stemming from
the protease inhibitors present within soy products that may not be subject to
extreme heat or pH change such as soy flour and soy milk. In previous studies
protein digestibility of soy was linked to pancreatic enlargement and possible
15

disease (Liener & Hasdai, 1986) and led to BBI being thought of as an
antinutrient, but this was later proven inaccurate as multiple studies showed that
in smaller concentrations, BBI could prove beneficial (Armstrong et al., 2000;
Losso, 2008). In addition, phase I randomized controlled trials on the safety of
BBI concentrate showed that the inhibitor concentrate was well tolerated by male
participants with no apparent toxicity and changes in hematological and
biochemical markers (Lin et al., 2014). BBI has been linked to chemoprevention
against different types of cancer such as colorectal cancer (Clemente, Marínmanzano, Arques, & Domoney, 2013), oral cancer (Armstrong et al., 2013;
William & Papadimitrakopoulou, 2013) and prostate cancer (Kennedy & Steven
Wan, 2002; Tang et al., 2009). In addition, BBI showed activity against aphid
parasitoid Aphidius ervi Haliday (Azzouz et al., 2005) and anti-viral properties
against human immunodeficiency virus? (Ma et al., 2016).

Kunitz Trypsin Inhibitor. The KTI family of protease inhibitors are larger than
BBI at around 20 kDa and contain fewer cysteine and disulfide bridges. KTI
family comes from different sources, first described from bovine pancreas and
then from soybeans (Kunitz, 1947). The soy-based KTI is defined by primarily
inhibiting serine-based proteases including trypsin by using the standard
mechanism (Laskowski & Kato, 1980). In soybean, KTI accounts for
approximately 74% of trypsin inhibition, and even though its inhibition site is able
to bind to trypsin and chymotrypsin (Bosterling & Quast, 1981), it does not bind
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as well to chymotrypsin (Chen et al., 2014), which is why the majority of studies
done thus far focus on BBI. Some of the proposed health benefits of KTI include
the inhibition of HIV reverse transcriptase (Fang, Wong, & Ng, 2010), which
could prove to be beneficial to HIV patients, and a reduction in inflammation
caused by elastase by inhibiting the enzyme (Ribeiro, Cunha, Fook, & Sales,
2010). In addition, soybean KTI showed different mechanisms of
chemopreventive properties including reduction of TNF-α by inhibiting nuclear
translocation of NF-κB (Kobayashi et al., 2005) and suppressing c-JUN Nterminal kinase signaling (Kobayashi et al., 2005). Anti-cancer properties of KTI
are associated with its ability to suppress urokinase expression leading to
reduced invasion and metastasis of cancer cells (Inagaki et al., 2005; Kobayashi
et al., 2004).

Inflammation and inflammasomes

Inflammation is a result of the innate immune system in response to dangers to
the host, such as cell injury, infection, and recognition of danger-associated
molecular pathways (DAMPs) and pathogen-associated molecular pathways
(PAMPs) (Ferrero-Miliani et al., 2007). Another name for this immune response
is acute inflammation, which is defined by pro-inflammatory molecules activating
the immune response and then switching to anti-inflammatory once the insult is
no longer a threat (Levy et al., 2001). If these pro-inflammatory molecules are
17

not switched off and the host system returns to a state of homeostasis, then this
results in chronic inflammation (Monteiro & Azevedo, 2010). Chronic
inflammation is a major problem within the host system because homeostasis is
not available, and this has been linked to metabolic diseases such as obesity and
type II diabetes (Hsieh et al., 2017), as well as neurodegenerative diseases such
as Parkinson’s and Alzheimer’s (Mao et al., 2017). One of the leading causes of
chronic inflammation is the inflammation cascade associated with sterile
stressors that are released by intracellular oligomers called inflammasomes
(Abais et al., 2015). The inflammasome is activated through a complex pathway
that is started with the recognition of a DAMP or PAMP which activates the Tolllike receptor protein 4 (TLR4), which activates the NF-κB that is responsible for
the translation of inflammasome associated proteins (Walsh, Muruve, & Power,
2014), and this portion is known as “priming”. Once the inflammasome is primed,
a stimulant such as ROS or ATP is needed to “activate” the inflammasome,
which converts pro-caspase into caspase-1 through thioredoxin-interacting
protein (TXNIP) binding to the inflammasome allowing cleavage just before the
active caspase-1 (Zhou et al., 2010). Once caspase-1 is activated, it cleaves the
immature pro-inflammatory cytokines interleukin-1ß and interleukin-18 into their
active forms, which are then expressed out of the cell and initiate the priming
step as before, creating a cascade of inflammation in neighboring cells (Tőzsér &
Benko, 2016).
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Abstract

Soybean contains several biologically active components and one of this
belong to the bioactive peptide group. The objectives of this study were to
produce different lunasin-enriched preparations (LEP) and determine the effect of
Bowman-Birk inhibitor (BBI) and Kunitz trypsin inhibitor (KTI) concentrations on
the stability of lunasin against pepsin-pancreatin hydrolysis (PPH). In addition,
the effect of KTI mutation on lunasin stability against PPH was determined. LEP
were produced by calcium and pH precipitation methods of 30% aqueous ethanol
extract from defatted soybean flour. LEP, lunasin-enriched commercially
available products and KTI control and mutant flours underwent PPH and
samples were taken after pepsin and pepsin-pancreatin hydrolysis. The
concentrations of BBI, KTI, and lunasin all decreased after hydrolysis, but they
had varying results. BBI concentration ranged from 167.5 to 655.8 µg/g prehydrolysis and 171.5 to 250.1 µg/g after hydrolysis. KTI concentrations ranged
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from 0.3 to 122.3 µg/g pre-hydrolysis and 9.0 to 18.7 µg/g after hydrolysis.
Lunasin concentrations ranged from 8.5 to 71.0 µg/g pre-hydrolysis and 4.0 to
13.2 µg/g after hydrolysis. In all products tested, lunasin concentration after PPH
significantly correlated with BBI and KTI concentrations. Mutation in two KTI
isoforms led to a lower concentration of lunasin after PPH. This is the first report
on the potential role of KTI in lunasin stability against PPH and must be
considered in designing lunasin-enriched products that could potentially survive
digestion after oral ingestion.
Keywords: soybean, BBI, KTI, lunasin, pepsin-pancreatin hydrolysis, protease
inhibitors

Introduction
Soybean is the most widely used legume throughout the world being used as a
source of food, oil and petroleum replacement in plastics and other items (Singh,
Kumar, Sabapathy & Bawa, 2008). It also contains biologically active
components with reported health benefits including isoflavones (Messina, 2014),
saponins (MacDonald et al., 2005) and biologically active peptides (Wang &
Gonzalez De Mejia, 2005). Biologically active peptides in soybean include the
naturally occurring Bowman-Birk inhibitor (BBI), Kunitz trypsin inhibitor (KTI) and
lunasin and peptides that are products of enzymatic hydrolysis and fermentation.
Lunasin belongs to the 2S soy albumin protein with 43 amino acid residues
whose biological activity is attributed to the presence of a cell adhesion motif
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composed of arginine-glycine-aspartic acid residues and a carboxylic acid tail
composed of 8 aspartic acid residues (Galvez & Lumen, 1999; Lule, Garg,
Pophely, Hitesh & Tomar, 2015). Lunasin possessed different potential biological
properties including anti-cancer (Shidal, Al-Rayyan, Yaddanapudi & Davis, 2016;
Jiang, Pan, Cheng, Li, Liu & Li, 2016;Hsieh, Hernández-Ledesma, Jeong, Park,
& de Lumen, 2010) anti-inflammatory (Dia, Wang, Oh, de Lumen & de Mejia,
2009; Cam & de Mejia, 2012; Cruz-Huerta et al., 2015; Hernández-Ledesma,
Hsieh,& de Lumen, 2009) and immunomodulating properties (Yang et al., 2015;
Tung et al., 2014). One potential issue on the use of lunasin as a
chemopreventive and chemotherapeutic agents is its susceptibility to digestion
as previous studies have shown that up to 97% of the lunasin is digested leading
to low nanomolar concentrations found in human plasma after ingesting 50 g of
soy protein (Dia, Torres, de Lumen, Erdman & de Mejia, 2009). One potential
strategy of decreasing the digestion of intact lunasin is through the action of
protease inhibitors such as BBI and KTI that are naturally present in soybean.
BBI is a protease inhibitor that belongs to cystine-rich group characterized by low
molecular weight (8 kDa for BBI) and large amounts of disulfide bonds (7 for BBI)
(Odani, Ikenaka & Bowman-Birk, 1973). BBI protects protein digestion by
inhibiting the activity of trypsin and chymotrypsin (Odani et al., 1973). Previous
studies have shown the capability of BBI to protect lunasin from hydrolysis
brought up by pepsin and pancreatin (Cruz-Huerta et al., 2015; Hsieh et al.,
2010). In addition, BBI has possible health benefits such as being a
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chemopreventative (Clemente, Marín-manzano, Arques & Domoney, 2013) and
anticarcinogenic agent (Kennedy, 1998). KTI is another protease inhibitor that is
larger than BBI with molecular weight of approximately 20 kDa and contains less
disulfide bridges. KTI also demonstrated different biological properties including
anticancer, anti-HIV1 reverse transcriptase and immunoregulating properties
(Fang, Wong & Ng, 2010; Inagaki et al., 2005). To date, no one has studied the
role of KTI on the stability of lunasin against pepsin-pancreatin hydrolysis (PPH).
The objectives of this study were to produce different lunasin-enriched
preparations (LEP) and determine the effect of protease inhibitors, Bowman-Birk
inhibitor and Kunitz trypsin inhibitor, concentrations on the stability of lunasin
against PPH.

Materials and Methods
Materials

Prolia defatted soy flour was purchased from Amazon and produced by Cargill
Mills (Minneapolis, MN). The commercially-available products (C-LEP)
(LunaRichX, designated as L and Now, designated as N) were from Reliv
(Chesterfield, MO). Control and KTI mutant soy flours were obtained as
previously reported (Gillman, Kim, & Krishnan, 2015). Lunasin polyclonal
antibody was raised in rabbit using the 15 amino acid corresponding to the Cterminus of lunasin (ProteinTech Group, Chicago IL), synthetic lunasin standard
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was synthesized by LifeTein LLC (New Jersey, USA), BBI standard was
purchased from Sigma-Aldrich (St. Louis, MO) and KTI standard was purchased
from VWR International (Atlanta, GA). All chemicals were purchased from
ThermoFisher Scientific and VWR International unless otherwise specified.

Preparation of lunasin-enriched samples and pepsin-pancreatin hydrolysis

Lunasin-enriched samples were prepared following the procedure described
earlier (Krishnan & Wang, 2015) with slight modifications. Briefly, 100g defatted
soy flour were mixed with 1-L 30% ethanol solution for 2 h at 20 to 22 °C. After
centrifugation (8,000 rpm, 4°C) for 30 min, the supernatant was collected and
calcium precipitation was accomplished by adding CaCl2 to a final concentration
of 10 mM and stirred for 10 min. After centrifugation as above the precipitate
was collected and dissolved in 1 volume distilled water and divided into four
parts. One part was called Ca LEP and the remaining 3 parts were split into three
groups and their pH adjusted to 3 (pH 3 LEP), 4 (pH 4 LEP) and 5 (pH 5 LEP).
After pH adjustment, samples were centrifuged as above and the precipitate was
collected, resuspended in 10 mL of Tris-buffered saline (TBS) and the pH was
readjusted to 7.5. The samples were dialyzed in a membrane with 3.5 kDa
molecular weight cut-off (Spectrum Labs, Rancho Dominguez, CA) frozen and
lyophilized. Samples were kept at -20 °C until analysis. PPH was performed as
previously reported (Cruz-Huerta et al., 2015) with some modifications. Briefly,
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30 mg of lyophilized sample was suspended in 10-mL water and pH adjusted to
2.0 and pepsin was added at 1:20 enzyme:LEP ratio. Pepsin hydrolysis was
carried out for 1 h at 37 °C in a shaking water bath after which 5-mL of the
mixture was taken, heated at 75 °C for 20 min to inactivate pepsin and
designated as pepsin digests. The pH of the remaining mixture was adjusted to
7.5 to inactivate pepsin; and pancreatin and bile extract were added at 1:20
enzyme:LEP ratio and 1:40 bile extract:LEP ratio, respectively. The pancreatin
hydrolysis was carried out for 1 h at 37 °C in a shaking water bath and pancreatin
was inactivated by heating at 75 °C for 20 min and called pepsin-pancreatin
digests. Digests were centrifuged at 20,000 x g for 30 min, supernatants were
dialyzed, freeze-dried and stored at -20 °C until used.

Soluble protein concentration by Bradford Assay

Ten mg of samples were extracted with 1-mL TBS by vortexing for 90 min at 20
to 22 °C, followed by centrifugation (20,000 x g, 4 °C) for 30 min and the
supernatant was used for the analysis based on Bradford (1976) principle. One
hundred µL of diluted supernatant (1:50) and different concentrations of bovine
serum albumin standards from 0 to 20 µg/mL were plated in 96-well plate and
100 µL of Quick StartTM Bradford dye reagent (Bio-Rad Laboratories, Hercules,
CA) were added. After 5 min of incubation at 20 to 22 °C, the absorbance was
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read at 630 nm and total soluble proteins were calculated using the generated
BSA standard curve equation.

Protein profile by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE)

SDS-PAGE under reducing condition was carried out by loading approximately
20 µg of protein in 4-20% Mini-Protean TGX gels (Bio-Rad Laboratories,
Hercules, CA) run at 100 volts for 100 minutes. Gels were stained with
approximately 50 mL Bio-safe Coomassie Stain (Bio-Rad Laboratories, Hercules
Inc.) overnight at 4 °C. Destaining was done by washing with water 3 times for 10
minutes each or until the background dye was removed.

Western Blot analysis

After the SDS-PAGE was run, gels were equilibrated in blotting buffer (20%
methanol in SDS-PAGE running buffer) for 15 min. Proteins were transferred
into Amersham™Hybond™ 0.45µm PVDF membrane (GE Healthcare,
Piscataway NJ) at 110 volts for 60 minutes at 4 °C. After the transfer, the
membrane was blocked with 5% non-fat dry milk in TBST for 60 min at 20 to 22
°C. After washing with TBST three times for 10 minutes each, the membrane
was incubated in primary antibody against lunasin, BBI (Gillman et al., 2015) and
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KTI (VWR International, Atlanta GA) at 1:2,000 dilution overnight at 4 °C. After
washing, membrane was incubated with anti-rabbit secondary antibody
(ThermoFisher Scientific) at 1:2000 dilution for 2 h at 20 to 22 °C. After washing,
blots were imaged by chemiluminescence using C-Digit blot scanner (Li-Cor
Biosciences, Lincoln, NE).

Enzyme-Linked Immunosorbant Assay (ELISA) for lunasin, BBI and KTI
concentrations

One hundred µL of diluted samples (1:2500), lunasin standard, BBI standard and
KTI standard were plated in triplicate on immuno-96 well plate (BrandTech) and
incubated for at least 14 h at 4 °C. Afterwhich, the plate was washed three times
with 300 µL washing buffer (1L PBS + 5 mL Tween 20, PBST) per well and
blocked with 300µl of 1% sodium caseinate in PBST for 1 h at 20 to 22 °C. After
washing, 50 µL of the primary antibody was added to each well and incubated for
1 h at 20 to 22 °C. After incubation and washing, 50 µL of secondary antibody
solution was added and incubated for 2 h at 20 to 22 °C. The secondary
antibody solution was removed and the plate was washed and 100µl of 3,3’,5,5’tetramethylbenzidine solution was added to each well and incubated for 30 min
at 20 to 22 °C in the dark. After 30 min, the reaction was stopped by adding
100µl of 2 M H2SO4, and the absorbance was read at 450nm. Lunasin, BBI and
KTI concentrations were calculated using their respective standard curve.
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Trypsin Inhibition Assay

Fifty µL of sample (200 µg soluble protein/mL), BBI (200 µg/mL) as positive
control or assay buffer (Tris buffer, pH 8.2) as blank were plated in 96-well plate
followed by 50 µL trypsin working solution (160 µg/mL) and incubated for 10 min
at 20 to 22 °C. After 10 minutes, 50 µl of N-α-benzoyl-D,L-arginine 4-nitroanilide
trypsin substrate (0.8 mg/mL) was added and incubated for 5 min at 20 to 22 °C.
The absorbance was read at 405nm. Trypsin inhibition was calculated using the
following formula: (Positive control average - sample
absorbance)/(200*0.05)*1000

Size-Exclusion Chromatography

The molecular weight profiles of the samples were analyzed by size exclusion
chromatography on an Agilent 1200 HPLC system (Agilent Technologies, Santa
Clara, CA) equipped with an autosampler (G1329A), a quaternary pump
(G1311A), a vacuum degasser (G1322A), a temperature controlled column
(G1316A) and a diode array detector (G1315D). The separation was performed
on a BioSep-SEC-S2000 column (300 X 7.80 mm, Torrance, CA). The mobile
phase was 45% acetonitrile in water with 0.1% trifluoroacetic acid at flow rate of
1.0 ml/min. The injection volume was 20µl with 20 min run time. The detector
was set at 214 nm and the analysis was performed at ambient temperature.
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Antioxidant Capacity

Oxygen radical antioxidant capacity (ORAC) assay. ORAC assay was done as
previously described (Mojica, Meyer, Berhow & de Mejia, 2015) briefly 20 µL of
sample, standard (240 to 4 µM Trolox), and blank were added 96-well plate in
triplicate followed by 120 µL of fluorescein (70nM final concentration) and
incubated at 37°C in the dark for 15 minutes. Afterwhich, 60 µL of 2,2’-azobis-(2methylpropionamidine) (12mM) was added to each well and the plate was read
at excitation of 485 nm and emission of 582 nm with a sensitivity of 60 every two
minutes for 120 minutes. ORAC values were calculated from Trolox standard
curve and reported as µM Trolox equivalent (TE).
Nitric Oxide Radical Scavenging Assay. Nitric oxide scavenging assay
was performed as previously described (Mojica, Meyer, Berhow & de Mejia,
2015), briefly 50 µL of samples and control were added in triplicate to two 96 well
plates, and 50 µl of water was added to each well. One plate received 25 µL of
100 mM sodium nitroprusside and the other received 25 µL of water, and both
plates were incubated for 2 hours at 20 to 22 °C in the dark. 100 µL of Griess
reagent (1:1 1% sulfanillic acid in 5% phosphoric acid, 0.1% N-(1-napthyl)ethylenediamine dihydrochloride) was added to each well and incubated for 15
min at 20 to 22 °C in the dark. Absorbance was read at 550 nm.
2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity.
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DPPH radical scavenging was performed as previously described (Dia, Pangloli,
Jones, McClure & Patel, 2016), briefly 100 µL of samples and control were plated
in triplicate in a 96 well plate and 100 µL of DPPH solution (2 mg DPPH
dissolved in 50 mL methanol) was added and incubated at 20 to 22 °C in the
dark for 30 minutes. The absorbance was read at 517nm.

KTI mutant flour

The preparation of the KTI mutant flours was done by adding 30 mg of flour per
10 mL of water and stirred for 90 min at 20 to 22 °C (unhydrolyzed). The
hydrolyzed samples contained 30 mg of flour per 10 mL of water and the
hydrolysis process was performed as described earlier. After the preparation of
pre- and post-hydrolysis samples, all samples underwent soluble protein
concentration, SDS-PAGE, ELISA, trypsin inhibition, size exclusion
chromatography and ORAC assays as previously described.

Statistical Analysis

All experiments were performed in at least three independent replicates. Data
were analyzed using PROC GLM procedure of SAS Version 9.4 and means were
separated using Tukey posthoc test and significance was reported at P < 0.05.
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Results

Protein concentration and protein profile of lunasin-enriched samples

Fig. 3.1a (all figures are listed at the end of this chapter as an appendix) shows
that C-LEP (N, L) have less soluble protein concentration (43.7 mg/g for N) than
LEP (108.4 mg/g for pH 4). LEP at pH 5 contained more soluble proteins (58.4
mg/g) after hydrolysis compared to C-LEP (23.6 mg/g). Fig. 3.1b shows the
protein profile of samples before and after hydrolysis; the large molecular weight
proteins were hydrolyzed indicated by disappearance of the higher weight bands
after PPH. Fig. 3.1c shows western blot bands for BBI, KTI, and lunasin
indicating the presence of these proteins in the samples and subsequent
reduction of signal after PPH.

Concentrations of protease inhibitors, BBI and KTI, are higher in LEP than
C-LEP

Fig. 3.2a shows the concentration of BBI present in lunasin-enriched products
before and after hydrolysis. N sample did not contain any BBI while the other
samples have BBI concentrations ranging from 167.5 to 655.8 µg/g prior to PPH.
In general, PPH led to reduction in BBI concentrations in all products. Fig. 3.2b
shows the concentration of KTI present in lunasin-enriched products before and
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after PPH. KTI concentrations ranged from 0.32 to 122.3 µg/g before PPH and
was generally reduced after PPH. Fig. 3.2c shows the capability of different
products to inhibit the activity of trypsin. N sample did not inhibit the activity of
trypsin while Ca sample exhibited the highest trypsin inhibition by 50.6 AU/mg
protein before PPH. After PPH, the capability of these samples to inhibit trypsin
activity was reduced with Ca sample inhibition at 12.0 AU/mg protein.
Lunasin concentration after hydrolysis correlates with BBI and KTI
concentrations in different lunasin-enriched products

Fig. 3.3a shows the concentration of lunasin present in lunasin-enriched
products before and after hydrolysis. In general, PPH led to the reduction of
lunasin concentrations. Prior to PPH, lunasin concentrations ranged from 8.5 (N)
to 71.0 µg/g (pH 3) and from 4.0 (L) to 13.2 µg/g (pH 3) after hydrolysis. Fig.
3.3b shows a positive correlation of BBI and KTI concentrations before hydrolysis
and the percentage residual lunasin concentrations after hydrolysis. Fig. 3.3c is
shows the Pearson correlation indicating that the correlations between lunasin
stability against PPH and BBI and KTI concentrations pre-hydrolysis are highly
significant (P < 0.0001).
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Molecular weight profile of lunasin-enriched products as determined by
size exclusion chromatography

Fig. 3.4a shows the chromatogram of pH 3 precipitated lunasin-enriched product
(non-hydrolyzed, pepsin digest, pepsin-pancreatin digest, top to bottom) and Fig.
3.4b shows table inset of all lunasin-enriched products in the various stages of
hydrolysis. As indicated, pepsin and pepsin-pancreatin hydrolysis led to a
reduction in higher molecular weight molecules which is in agreement with the
protein profile as shown by the SDS-PAGE gels in Fig. 3.1b. For instance, pH 3
sample molecular weight distribution before PPH was 10.6% <1kda, 3.5% 15kda, 6.0% 5-10kda, 79.8% >10kda. After PPH, this distribution was changed to
29.3% <1kda, 18.9% 1-5kda, 15.6% 5-10kda, 36.1% >10kda.

Antioxidant capacity of lunasin-enriched products

Fig. 3.5a shows the ORAC values for LEP and C-LEP with values ranging from
79.41 to 176.92 µM TE. ORAC values indicated similar capability of samples to
scavenge oxygen radicals with only L significantly lower than the rest of the
samples. Fig. 3.5b and 3.5c show antioxidant scavenging potential by Nitric
Oxide and DPPH, respectively. In general, lunasin-enriched products were not
capable of scavenging both NO and DPPH radicals.
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Effect of KTI mutations on the concentrations of bioactive peptides in
soybean and their stability against pepsin-pancreatin digestion.

Fig. 3.6a shows the protein profile of the control, KTI-1 mutant, and KTI-1,3
mutant soybean flour before and after PPH. Large molecular weight bands
disappeared adter PPH. Samples had protein concentrations ranging from 47.2
(KTI-1,3) to 89.7 mg/g (KTI-1) prior to PPH and from 16.5 (KTI-1,3) to 21.2 mg/g
(KTI-1) after hydrolysis (Fig. 3.6b) indicating reduction of protein concentrations
after PPH. Fig. 3.6c shows BBI concentrations of samples ranging from 46.4
(KTI-1,3) to 83.6 µg/g (KTI-1) prior to PPH and from 6.2 (KTI-1,3) to 7.2 µg/g
(KTI-1) after PPH and Fig. 3.6d shows the reduction of KTI in KTI mutant flours
after hydrolysis with KTI concentrations ranged from 34.4 (KTI-1,3) to 52.9 µg/g
(Control) before PPH and from 5.4 (KTI-1) to 8.4 µg/g (Control) after PPH.
Control, KTI-1, and KTI-1,3 flour contained lunasin 32.5, 35.1, and 32.7 µg/g prior
to hydrolysis and reduced to 4.0, 3.3 and 2.8 µg/g, respectively, after hydrolysis
(Fig. 3.6e). Fig. 3.6f shows trypsin inhibitory capability of the samples ranging
from 59.1 AU/mg protein (KTI-1) to 64.9 (KTI-1,3) pre-hydrolysis. ORAC values
ranged from 193.2 µM TE (KTI-1) to 237.0 µM TE (control) as shown in Fig.
3.6g. After PPH, ORAC values ranged from 145.4 µM TE for control to 147.3 µM
TE for both of the KTI mutant flours. Fig. 3.7 shows the representative
chromatograms of KTI-1 mutant flour (unhydrolyzed, pepsin-hydrolyzed and
pepsin-pancreatin-hydrolyzed; from top to bottom) and the molecular weight
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distribution for all three sample before and after PPH. PPH led to reduction in
high MW molecules in all samples.

Discussion

Soy is one of the most abundantly produced crops in the U.S., with 3.93B barrels
being produced stateside (USDA National Agricultural Statistics Service, 2016).
Previous studies have shown the effects of mutations on the KTI gene within soy
(Gillman, Kim, & Krishnan, 2015), and the effects of the Bowman-Birk Inhibitor on
the stability of lunasin (Cruz-Huerta et al., 2015), but to our knowledge our study
is the first to demonstrate the effect of Kunitz trypsin inhibitor and Bowman-Birk
inhibitor on the stability of the bioactive peptide lunasin. Lunasin has been shown
to have multiple health benefits, hence ways of protecting it from the action of
digestive enzymes is one way to increase the potential biological effects of
lunasin in the human body. It has been shown in previous studies that lunasin
can be found in the plasma after eating simple soy products (Dia, Torres, De
Lumen, Erdman, & De Mejia, 2009), not LEP indicating that consumption of LEP
with optimum level of protease inhibitor could lead to even higher bioavailability
of this bioactive peptide. In this study, we used pH precipitation method to
potentially concentrate lunasin in a previously reported lunasin-enriched
preparation using calcium precipitation (Krishnan & Wang, 2015). The calciumprecipitated sample was adjusted to pH 3, 4 and 5 owing to the isoelectric point
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of soy protein (~4.5 pH) causing different proteins and different concentrations of
proteins to precipitate (Gennadios, Brandenburg, Weller, & Testin, 1993).
Though there is an increase in lunasin concentration in pH 3 sample, the protein
profile of the three pH precipitated samples did not differ with the protein profile
of the Ca precipitated sample indicating that there is no increase in lunasin purity.
We then compared the concentrations of lunasin, BBI and KTI of our LEP with CLEP, LunarichX and Now. Results showed that our LEP have higher
concentrations of these bioactive peptides than C-LEP. Notably, the
concentrations of BBI and KTI in C-LEP are very low indicating the potential
effect of processing methods used in production of C-LEP. Previous studies have
shown that processing could lead to reduction in the concentrations of BBI and
KTI. Heat-induced protein aggregation led to reduction in KTI and BBI in soymilk
(Chen, Xu, Zhang, Kong&Hua, 2014) while germination and hydrolysis led to
modification of these protease inhibitors (Dia, Gomez, Vernaza, Berhow, Chang
& de Mejia, 2012). As expected, pepsin and pepsin-pancreatin hydrolysis led to
reduction in the concentration of these bioactive peptides (Fig. 3.2 and 3.3)
leading to production of low molecular weight peptides as evidenced in SDSPAGE profile (Fig. 3.1b) and molecular weight distribution profile as determined
by size exclusion chromatography (Fig. 3.4) of the samples. The low
concentrations of KTI and BBI led to lower percentage retention in C-LEP as
compared to LEP as shown by strong correlations between BBI concentration
and percentage residual lunasin after pepsin and pepsin-pancreatin hydrolysis
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and KTI concentration and percentage residual lunasin after pepsin and pepsinpancreatin hydrolysis (Fig. 3.3b and 3.3c). Interestingly, in Now (Fig. 3.4b) and
control, KTI-1 and KTI-1,3 (Fig. 3.7b) samples, the percentage of molecules with
less than 1 kDa prior to hydrolysis is higher than pepsin digests. This could be
explained by the starting materials used, Now is a commercially available product
containing vitamins, minerals and a proprietary blend of different plant extracts
while control, KTI-1 and KTI-1,3 samples are prepared from whole soybean flour.
On the other hand, LEP samples were obtained from defatted soybean flour.
Looking at the molecular weight distribution of molecules with molecular weight
less than 5 kDa, pepsin digests consistently showed lower percentage as
compared to pepsin-pancreatin digests, for instance pepsin-hydrolyzed Ca has
32.6% of less than 5 kDa molecules while pepsin-pancreatin hydrolyzed Ca has
34.4% of less than 5 kDa molecules. This is true for other LEP samples: 37.2 vs
48.2% for pH 3; 26.9 vs 46.1% for pH 4; 31.8 vs 36.2% for pH 5, 84.6 vs 93.2%
for LR and 75.3 vs 91.8% for Now (Fig. 3.1b and Fig. 3.4b). The high
percentage of these low molecular weight molecules in C-LEP than our LEP
further shows the importance of BBI and KTI in protecting high molecular weight
compounds from protease digestion. The increase in the percentage of >10 kDa
in Now sample after pepsin hydrolysis may be explained by potential crosslinking
effect as mediated by other ingredients present in Now such as a proprietary
blend plant extract that may contain certain polyphenols. Procyanidine increased
the ultimate tensile strength and elongation of gelatin membranes (Chen, Wang
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& Jiang, 2012) while soy protein isolate-ogaja fruit extract reinforced crosslinking
of protein networks in the development of gluten-free rice noodle (Lee, Kim,
Song, Lee, Lee & Yoo, 2016). The pancreatin used in this study is composed of
trypsin, amylase, lipase, ribonuclease and other proteases as such will be able to
hydrolyze proteins, fats and starch. Other peptidases with potential hydrolytic
activity found in human plasma and gastrointestinal tract include kallikrein,
elastase, collagenase, gelatinase, carboxypeptidase and aminopeptidase.
Kunitz-type trypsin inhibitor isolated from seeds of Enterolobium contortisiliquum
was capable of inhibiting human plasma kallikrein and human neutrophil
elastase, which could potentially explain their capability to inhibit the growth of
different human cancer cells (Nakahata et al., 2011). On the other hand, HcPI
inhibitor isolated from Hermodice carunculata was able to inhibit pyroglutamyl
aminopeptidase II but not the activities of serine, cysteine, aspartic and other
metallo proteinases (Pascual et al., 2004). These previous studies demonstrated
the specificity of protease inhibitors which could have potential impact on
preserving the structure and biological activities of bioactive peptides such as
lunasin. Previous studies indicated the protective role of BBI on lunasin
digestibility but to our knowledge this is the first report on the potential protective
role of KTI on lunasin digestibility. To further investigate the role of KTI in lunasin
stability against pepsin-pancreatin hydrolysis, two soybean flours with mutations
in KTI gene was used and compared their behavior with a control soybean flour.
KTI mutation in KTI-1 isoform did not lead to significantly different residual
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lunasin concentrations while mutation in KTI-1 and KTI-3 isoforms led to
significantly lower residual lunasin concentrations than the control soybean flour.
After pepsin-pancreatin hydrolysis, the percentage residual lunasin in control
soybean flour is 12.3% which is higher than the percentage residual lunasin in
KTI-1 mutant flour of 9.4% and KTI-1,3 mutant flour of 8.6%. There results for the
first time demonstrated the possible role of KTI in the stability of lunasin against
pepsin-pancreatin hydrolysis. Measurement of the antioxidant activity of the
samples showed no potential effect of KTI mutations nor pepsin-pancreatin
hydrolysis on the ORAC values of the samples.
In summary, we report here the effect of protease inhibitor concentrations on the
stability of lunasin against pepsin-pancreatin hydrolysis. BBI concentration
positively correlated with lunasin stability. For the first time, we demonstrated that
in addition to BBI, KTI also play an important role in protecting lunasin from
pepsin-pancreatin hydrolysis. These factors must be considered in the production
of lunasin-enriched dietary supplements in order to ascertain the consumer of the
potential health-benefits associated with intake of such supplement.
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Appendix
Figures
Fig. 3.1. a) Commercially available products have less soluble protein
concentration than laboratory-prepared lunasin-enriched products. Bars with
different letter are significantly different from each other (P < 0.05, n = 3). Pepsinpancreatin hydrolysis led to a significant reduction in the protein concentration of
lunasin-enriched preparation as designated by * (P < 0.05) and ** (P < 0.001). b)
Protein profile of lunasin-enriched preparations as affected by pepsin and pepsinpancreatin digestion. Lanes 1 (Ca ppt), 2 (Ca-pepsin hydrolyzed), 3 (Ca-pepsinpancreatin hydrolyzed), 4, (pH 3 ppt), 5 (pH 3 ppt-pepsin hydrolyzed), 6 (pH 3
ppt-pepsin-pancreatin hydrolyzed), 7 (pH 4 ppt), 8 (pH 4 ppt-pepsin hydrolyzed),
9 (pH 4 ppt-pepsin-pancreatin hydrolyzed) Lanes 10 (pH 5 ppt), 11 (pH 5-pepsin
hydrolyzed), 12 (pH 5-pepsin-pancreatin hydrolyzed), 13 (LunarichX, L), 14
(LunarichX, L-pepsin hydrolyzed), 115 (LunarichX, L-pepsin-pancreatin
hydrolyzed), 16 (Now, N), 17 (Now, N-pepsin hydrolyzed), 18 (Now, N-pepsinpancreatin hydrolyzed) and MW: molecular weight marker. c) Western blot profile
showing the presence of BBI, KTI and lunasin in different lunasin preparations
and commercially available products as affected by pepsin-pancreatin digestion.
Lanes 1 (Ca ppt), 2 (Ca-pepsin hydrolyzed), 3 (Ca-pepsin-pancreatin
hydrolyzed), 4, (pH 3 ppt), 5 (pH 3 ppt-pepsin hydrolyzed), 6 (pH 3 ppt-pepsinpancreatin hydrolyzed), 7 (pH 4 ppt), 8 (pH 4 ppt-pepsin hydrolyzed), 9 (pH 4
ppt-pepsin-pancreatin hydrolyzed).
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Fig. 3.1. continued
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Fig. 3.2. Pepsin-pancreatin hydrolysis affected the concentrations of protease
inhibitors BBI and KTI as well as trypsin inhibitory activity of different lunasin
preparations and commercially available products. a) Commercially available
products have less BBI concentrations than laboratory-prepared lunasin-enriched
products. Bars with different letter(s) are significantly different from each other (P
< 0.05, n = 3). BBI was not detected in N product. Pepsin-pancreatin hydrolysis
led to a significant reduction in the BBI concentrations of lunasin-enriched
preparation as designated by * (P < 0.001) and ** (P < 0.0001) except for L
product. b) Commercially available products have less KTI concentrations than
laboratory-prepared lunasin-enriched products. Bars with different letter(s) are
significantly different from each other (P < 0.05, n = 3). KTI was not detected in N
product. Pepsin-pancreatin hydrolysis led to a significant reduction in the KTI
concentrations of lunasin-enriched preparation as designated by * (P < 0.001)
and ** (P < 0.0001). c) Commercially available products have less trypsin
inhibitory capacity than laboratory-prepared lunasin-enriched products. Bars with
different letter(s) are significantly different from each other (P < 0.05, n = 3).
Pepsin-pancreatin hydrolysis led to a significant reduction in the trypsin inhibitory
capacity of lunasin-enriched preparation as designated by * (P < 0.05) and ** (P
< 0.0001) except for commercially available N product.
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Fig. 3.2. continued
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Fig. 3.3. Lunasin stability against pepsin-pancreatin digestion is affected by the
concentrations of protease inhibitors BBI and KTI in different lunasin-enriched
preparations and commercially available products. a) Commercially available
products have less lunasin concentrations than laboratory-prepared lunasinenriched products. Bars with different letter(s) are significantly different from each
other (P < 0.05, n = 3). Pepsin-pancreatin hydrolysis led to significant reduction
in the lunasin concentrations of lunasin-enriched preparation as designated by *
(P < 0.0001). b) Concentrations of protease inhibitors BBI and KTI positively
correlated with the percentage residual lunasin concentrations after pepsin and
pepsin-pancreatin digestions indicating that BBI and KTI have protective effects
on lunasin against enzymatic digestion. c) An inset table shows the correlation
coefficient and P-values for lunasin percentage residual concentrations after
pepsin and pepsin-pancreatin digestion as affected by BBI and KTI
concentrations.
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Fig. 3.3. continued
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66

Fig. 3.4. Molecular weight distribution of lunasin enriched samples. a)
Chromatogram of pH 3 precipitated lunasin-enriched product (non-hydrolyzed,
pepsin digest, pepsin-pancreatin digest in descending order), and b) Table inset
of all lunasin-enriched products in the various stages of hydrolysis (sample name
indicates no hydrolysis, P = Pepsin digest, PP = pepsin-pancreatin digest) which
shows a reduction in higher weight molecules after hydrolysis.
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Fig. 3.4. continued
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Fig. 3.5. Antioxidant activity of lunasin-enriched preparations is associated with
oxygen radical scavenging but not to nitric oxide and DPPH radicals scavenging.
a) ORAC values for lunasin-enriched preparations are significantly higher than
LunaRichX but similar to Now. b) Lunasin-enriched preparations do not possess
the capability to scavenge NO radicals and c) Lunasin-enriched preparations do
not possess the capability to scavenge DPPH radicals.

69

Fig. 3.5. continued
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Fig. 3.6. Effect of KTI mutations on the concentrations of bioactive peptides in
soybean and their stability against pepsin-pancreatin digestion. a)
Electrophoresis profile showing degradation of proteins after pepsin and pepsinpancreatin digestion Lanes MW: molecular weight marker, 1: control soy flour, 2:
control after pepsin hydrolysis, 3: control after pepsin-pancreatin hydrolysis, 4:
KTI-1 mutant soy flour, 5: KTI-1 mutant soy flour after pepsin hydrolysis, 6: KTI-1
mutant soy flour after pepsin-pancreatin hydrolysis, 7: KTI-1,3 mutant soy flour,
8: KTI-1,3 mutant soy flour after pepsin hydrolysis, 9: KTI-1,3 mutant soy flour
after pepsin-pancreatin hydrolysis; b) KTI-1 mutant soy flour has higher soluble
protein concentration than control flour (#, P = 0.0099) while KTI-1,3 mutant soy
flour has lower soluble protein concentration than control flour (*, P = 0.0250).
After pepsin and pepsin-pancreatin hydrolysis, KTI mutation did not affect soluble
protein concentration; c) BBI concentration of KTI-1 mutant soy flour is
significantly higher than control soy flour (#, P = 0.0016) while BBI concentration
of KTI-1,3 mutant soy flour is significantly lower than control soy flour (*, P =
0.0153). KTI-1,3 mutation led to a significantly lower residual BBI concentration
than control soy flour after pepsin-pancreatin hydrolysis. d) KTI mutation led to a
significantly lower KTI concentration in KTI-1 mutant flour (* P = 0.0366) and KTI1,3 mutant flour (**, P < 0.0001) than control soy flour. Pepsin and pepsinpancreatin hydrolyzates of KTI mutant flours have lower residual KTI
concentrations that control flour (**, P < 0.0001); e) KTI mutation did not affect
the concentration of lunasin in unhydrolyzed and pepsin-hydrolyzed soy flour
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while KTI-1,3 mutation led to a significantly lower residual lunasin concentration
after pepsin pancreatin hydrolysis than control soy flour (*, P = 0.0474); f) KTI
mutation did not affect the capability of soy flour to inhibit trypsin activity and G)
KTI mutation did not affect the antioxidant capacity of soy flour extract as
measured by ORAC. Pepsin-pancreatin hydrolysis led to significant lower
concentrations of all parameters measured.
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Fig. 3.6. continued
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Fig. 3.7. Molecular weight distribution of control, KTI-1 mutant and KTI-1,3
mutant flours as affected by pepsin and pepsin-pancreatin hydrolysis. a)
Representative chromatograms of KTI-1 mutant flour (unhydrolyzed, pepsinhydrolyzed and pepsin-pancreatin-hydrolyzed; from top to bottom) and b) Table
inset showing the molecular weight distribution for unhydrolyzed, pepsinhydrolyzed (P) and pepsin-pancreatin hydrolyzed (PP) soy flours.
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Fig. 3.7. continued
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CHAPTER IV
LUNASIN-ENRICHED MATERIAL INHIBITS ACTIVATION OF THE
INFLAMMASOMES IN THP-1 HUMAN MACROPHAGES BY
REDUCING REACTIVE OXYGEN SPECIES
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Abstract
Inflammation caused by the NLRP3 inflammasome has been linked to many
diseases, and multiple pathways to activate the inflammasome have been
described using different signals including the production of reactive oxygen
species.Lunasin, a bioactive peptide in soybean, was previously reported to
inhibit nuclear factor of kappa B-mediated transcription, first step in
inflammasomes activation. The objective was to determine the ability of lunasinenriched preparation (LEP) to inhibit inflammasomes activation in vitro using
THP-1 human macrophages. THP-1 human monocytes were differentiated into
macrophages with cells using phorbol 12-myristate 13-acetatebefore being
treated with different concentrations of LEP (0.0625 to 0.25 mg/mL) in the
presence of 1 µg/mL lipopolysaccharide as the priming signal for 6 hours. After
priming, inflammasomes were activated by adding 5 mMadenosine triphosphate.
Unhydrolyzedd LEP treatment at 0.25 mg/mL led to inhibition of IL-1β and IL-18
release in the cell culture supernatant by 52.0 and 49.6%, respectively. In
addition, LEP treatment inhibited the production of intracellular reactive oxygen
species (ROS) in THP-1 human macrophages without affecting the expressions
of NLRP3 and ASC proteins involved in activation of inflammasomes. Pepsinpancreatin hydrolysis reduced the ability of LEP to inhibit production of
intracellular ROS. Our results showed that LEP inhibited activation of
inflammasomes by reducing intracellular ROSs in vitro.
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Introduction

Inflammation occurs when pattern recognition receptors (PRRs) identify
exogenous pathogen-associated molecular patterns (PAMPs) and damageassociated molecular patterns (DAMPs) (Abais, Xia, Zhang, Boini, & Li, 2015).
PAMPs are molecules associated with pathogens and infection, such as
lipopolysaccharide (LPS), an endotoxin associated with gram-negative bacteria
(Kulp & Kuehn, 2012). LPS is recognized by the pattern recognition receptor,
PRR Toll-Like Receptor 4 (TLR4) which activates nuclear factor kappa-lightchain-enhancer of activated B cells (NF-κB) (Lu, Yeh, & Ohashi, 2008). DAMPs
are molecules that are associated with internal cellular damage and activate NFκB (Rubartelli & Lotze, 2007). A novel theory is that mitochondrial reactive
oxygen species (ROSs) are produced after the cell has been damaged, and
induce the priming step of inflammasome activation in which NF-κB transcribes
the components of the inflammasome, particularly pro-interleukin-1ß (pro-IL-1ß)
and nucleotide-binding oligomerization domain, leucine rich repeat and pyrin
domain containing 3 (NLRP3) (Tőzsér & Benko, 2016). After priming, DAMPs
and PAMPs cause NLRP3 oligomerization and bind to apoptosis-associated
speck-like protein containing a caspase-recruitment domain (ASC) which then
binds to pro-cysteine-aspartic protease-1 (pro-caspase-1), resulting in a large
oligomer that activates caspase-1 (Tschopp & Schroder, 2010). Once activated,
caspase-1 is able to cleave pro-IL-1ß, resulting in the mature IL-1ß which is then
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expressed out of the cell and acts as a cytokine, resulting in a cascade of
inflammation (Haneklaus, O’Neill, & Coll, 2013). Inflammasomes are associated
with chronic inflammation which can damage the integrity of cells, resulting in
diseases such as Alzheimer’s, type II diabetes, atherosclerosis, and gout (Abais
et al., 2015).
Lunasin is a bioactive peptide found in soy with a unique amino acid
sequence that includes an arginine-glycine-aspartic acid motif(Lule, Garg,
Pophaly, Hitesh, & Tomar, 2015). Previous studies have shown the potential of
lunasin to act as a chemopreventive agent (Dia & Mejia, 2010; Shidal, AlRayyan, Yaddanapudi, & Davis, 2016;Cruz-Huerta et al., 2015; HernándezLedesma, Hsieh, & de Lumen, 2009; Hsieh, Chou, & Wang, 2017). This
chemopreventive property of lunasin may be associated with its ability to inhibit
inflammation through NF-κB signaling in THP-1 human macrophages (Cam and
de Mejia, 2012), the priming step in inflammasome activation. This led us to ask
if lunasin-enriched preparation (LEP) can inhibit inflammasomes activation in
THP-1 human macrophages.
This study aims to evaluate the ability of LEP to inhibit activation of the
inflammasomes in vitro and determine the potential mechanism of action. In
addition, the effect of pepsin-pancreatin hydrolysis in LEP bioactivity was
evaluated.
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Materials and Methods
Materials

Prolia defatted soy flour was purchased from Amazon and produced by Cargill
Mills (Minneapolis, MN). THP-1 human leukemia monocyte cells were obtained
from American Type Culture Collection (Manassas, VA).Roswell Park Memorial
Institute-1640 (RPMI) growth media was obtained from Corning Inc. (Conring,
NY). Fetal Bovine Serum (FBS) was obtained from Life Tech (Carlsbad, CA).
LPS and Phorbol 12-myristate 13-acetate (PMA) were obtained from SigmaAldrich Corp. (St. Louis, MO). Primary antibodies (ASC 10500-1-AP, Beta-actin
60008-1-I9, caspase-1 22915-1-AP, and IL-1ß 60136-1-Ig) were obtained from
Proteintech Group Inc. (Chicago, IL). Secondary antibodies (Goat anti-mouse
926-80010, goat anti-rabbit 926-80011) were obtained from Li-Cor Biosciences
Inc.(Lincoln, NE). ELISA kit for IL-1ß was obtained from BioLegend Inc. (San
Diego, CA) and IL-18 kit was purchaseded from Research and Diagnostics
Systems Inc.(Minneapolis, MN).
LEP preparation was done by stirring 100g defatted soy flour with 1-L 30%
ethanol solution for 2 h at 20 to 22 °C, then followed by centrifugation (8000 rpm,
4 °C) for 30 min. The supernatant was then collected and calcium precipitation
was accomplished by adding CaCl2 to a final concentration of 10 mM and stirred
for 10 min. After centrifugation as above, the precipitate was collected and
dissolved in 1 volume distilled water before dialysis with a 3.5kDa molecular
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weight cutoff membrane (Spectrum Labs, Rancho Dominguez, CA) then frozen
and lyophilized.

Protein profile by size-exclusion chromatography and high-performance
liquid chromatography

The molecular weight profile of the sample was analyzed by size exclusion
chromatography on an Agilent 1200 HPLC system (Agilent Technologies, Santa
Clara, CA) equipped with an autosampler (G1329A), a quaternary pump
(G1311A), a vacuum degasser (G1322A), a temperature controlled column
(G1316A) and a diode array detector (G1315D). The separation was performed
on a BioSep-SEC-S2000 column (300 × 7.80 mm, Torrance, CA). The mobile
phase used was 45% acetonitrile in water with 0.1% trifluoroacetic acid at flow
rate of 1.0 mL/min. The injection volume was 20 μL with 20 min run time. The
detector was set at 214 nm and the analysis was performed at ambient
temperature

Cell culture and treatment

THP-1 human leukemia monocyte cells were cultured using RPMI 1640 that
contained 10% FBS, 1% penicillin-streptomycin, 1% sodium pyruvate, 10mM
HEPES, and 50µM ß-mercaptoethanol. After the cells were allowed to
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proliferate, they were treated with 162nM of PMA to allow differentiation into
macrophage-like cells as previously described (Montoya-Rodríguez, de Mejía,
Dia, Reyes-Moreno, & Milán-Carrillo, 2014) with slight modification. Cells were
seeded into 6 and 12-well plates at a concentration of 500,000 cells/mL and
differentiation occurred for 24h at 37°C in a 5% CO2/95% air incubator. After
differentiation, the cells were treated with 0.25, 0.125, and 0.0625mg/ml LEP in
the presence of 1 µg/mL LPS for 6 h. After 6 h, ATP was added at 5 mM to treat
cells for another hour. Negative control cells were left in plain RPMI. The
concentration of LEP did not affect viability of THP-1 cells as determined by MTS
assay.

Whole cell lysates preparation and cell culture supernatant collection

After the cells were treated, the plates were placed on ice while the supernatant
was collected in microcentrifuge tubes, then the cells were washed with ice cold
PBS twice to remove cell debris. After washing, 100 µL of RIPA lysis buffer
(protease inhibitor cocktail to RIPA 1:100) was added to each well and incubated
for 5min at 4°C. Cells were harvested using cell scrapers and added to prechilled microfuge tubes, then vortexed for 5min at 4°C before being centrifuged at
14,000 x g for 10min at 4°C. The supernatant was then collected and the pellet
discarded. Bradford protein analysis assay was performed to determine protein
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concentration using bovine serum albumin as the standard, before denaturation
with Laemmli buffer containing 5% ß-mercaptoethanol and boiling for 5 minutes.

Western blot for NLRP3 and ASC

SDS-PAGE under reducing condition was carried out by loading approximately
10 μg of protein in 4–20% Mini-Protean TGX gels (Bio-Rad Laboratories,
Hercules, CA). After the SDS-PAGE was runat 200 V for 35 min, gels were
equilibrated in blotting buffer (20% methanol in SDS-PAGE running buffer) for
15 min. Proteins were transferred into Amersham™Hybond™ 0.45 μm
polyvinylidene fluoride membrane (GE Healthcare, Piscataway NJ) at 110 V for
60 min at 4 °C. After the transfer, the membrane was blocked with 5% non-fat dry
milk in TBST for 60 min at 20 to 22 °C. After washing with TBST three times for
10 min each, the membrane was incubated in primary antibody againstNLRP3
(NOD-like receptor family pyrin domain containing 3), ASC (Apoptosis-associated
speck-like protein containing a CARD) at a 1:2000 dilution, and Beta-actin at a
1:5000 (Proteintech Group, Chicago IL) for 3 h at 20 to 22 °C. After incubation,
the membrane was washed as described previously, and incubated with
secondary antibodies at a 1:1000 for 1.5 h at 20 to 22 °C(goat anti-rabbit for ASC
and NLRP3, and goat anti-mouse for Beta-actin). After washing as above, 300µl
of a 1:1 mixture of WesternSure Premium stable peroxide and luminol enhancer
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was added and the membrane was imaged by chemiluminescence using C-Digit
blot scanner (Li-Cor Biosciences, Lincoln, NE). Membranes were stripped for
reprobing with β-actin using a mild stripping buffer twice for 10 min, followed by a
wash with PBS twice for 10 min, then washed with TBST twice for 5 min before
being blocked as described previously.

Measurement of intracellular reactive oxygen species

Fluorescence microscopy. THP-1 cells were treated as described previously.
After the treatment, the plate was placed on ice and the supernatant was
removed by pipetting before the cells were washed with 500 µL ice-cold PBS
twice. After washing, 1 mL of 10 µM 2’7’-dichlorofluoroscein diacetate was
added to each well before being incubated at 37°C for 10 min in a 5% CO2
incubator. After incubation, the dye was removed and the cells were washed
with PBS twice before pictures were taken using a 20x magnification green
fluorescent protein (GFP) channel on an Evos microscope (Thermo Fisher
Scientific, Waltham MA).
Fluorescence spectrophotometry. THP-1 cells were treated and harvested as
described previously, and after the wash step, 200 µL of a 0.25% trypsin in 1mM
ethylenediaminetetraacetic acid was added to each well and incubated for 5 min
to detach cells from the plate. After incubation, 800 µL of complete RPMI was
added to inactivate trypsin, and the media was collected and centrifuged at 500 x
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g for 5 min. The supernatant was then discarded and the pellet was resuspended in 500 µL of PBS containing 10 µM 2’7’-dichlorofluoroscein diacetate
and incubated for 30 min at 37°C in a 5% CO2 incubator before being vortexed
and 200 µL of the suspension was plated in duplicate on a 96-well plate and read
with a fluorescence intensity at 485 nm/528 nm.
Flow cytometry. THP-1 cells were treated the same as described in fluorescence
spectrophotometry, except the number of cells with green fluorescence and
intensity were measured using an FL 1 channel (FITC) on a MACSQuant flow
cytometer from (Miltenyi Biotec Inc., Bergisch Gladbach, Germany).

Measurement of released interleukin-1ß and interleukin-18 in the cell
culture supernatant by enzyme-linked immunosorbent assay (ELISA)

Interleukin-1ß. Measurement ofextracellular IL-1ß that was released into the
supernatant was performed by ELISA, using a Human IL-1ß ELISA MAX™
Deluxe Set obtained from BioLegend Inc. (San Diego, CA). One hundred µL of
detection antibody was added to an uncoated 96-well ELISA plate and incubated
for at least 14 h at 4°C. After incubation, the plate was washed with 300 µL of
washing buffer (0.5% Tween 20 in PBS) four times, then blocked by adding 200
µL of assay diluent A and incubated for 1 h on an orbital shaker at approximately
50rpm at 20 to 22 °C. After blocking, the plate was washed as previously
described, and 50 µL of Assay Buffer D and 50 µL of diluted samples (1:50) and
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standard were added in duplicate and incubated for 2 h under the same
conditions. After incubation with the samples, the plate was washed again and
100 µL of diluted Detection Antibody were added to each well and incubated for 1
h under the same conditions. After washing, 100 µL of diluted avidin-horseradish
peroxidase solution was added to each well and incubated for 30 min under the
same conditions. Then, the plate was washed 5 times with 30 s of soaking
between each wash, and 100 µL of substrate solution F was added and
incubated in the dark for 20 min before adding 100 µL of 2 N H2SO4 to stop the
reaction. The plate was immediately read at 450 nm using a Cambrex microplate
reader (BioTek Inc, Winooski, VT).
Interleukin-18. Measurement of interleukin-18 that was released into the
supernatant was performed using an ELISA kit obtained from R&D Systems
(Research and Diagnostics Systems Inc., Minneapolis MN) and slight
modifications to the IL-18 method: the detection antibody was incubated for 2 h,
and streptavidin-HRP was incubated for 30 minutes.

Statistical Analysis

All experiments were performed in at least three independent replicates. Data
were analyzed using PROC GLM procedure of SAS Version 9.4 (SAS Institute,
Car, NC) and means were separated using Tukey posthoc test and significance
was reported at P < 0.05.
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Results
Characterization of lunasin-enriched preparation

Fig. 4.1a (all figures are listed in the appendix of this chapter) shows the size
exclusion chromatography profile of LEP before and after pepsin-pancreatin
hydrolysis. As shown, pepsin-pancreatin hydrolysis led to digestion of high
molecular weight compounds to low molecular weight molecules. In addition,
HPLC analysis (Fig. 4.1b) showed that pepsin-pancreatin hydrolysis led to
reduction of intact lunasin in LEP.
Effect of lunasin-enriched preparation on secretion of IL-1β and IL-18 in cell
culture supernatant

Fig. 4.2a shows the effect of different treatment regimens on the production of IL1ß by THP-1 human macrophages. Compared to untreated cells producing a
small amount of IL-1ß, addition of LPS led to a significant increase in the amount
of IL-1ß produced. Addition of ATP led to further increase in IL-1ß indicating
activation of inflammasome. LEP treatment led to a significant reduction of IL-1ß
secretion indicating the ability of LEP to inhibit inflammasome activation.
Unhydrolyzed LEP at 0.25 mg/mL reduced IL-1ß secretion by 52.0% while
hydrolyzed LEP at the same concentration reduced IL-1ß secretion by 75.9%.
Fig. 4.2b shows the effect of different treatments on IL-18 production by THP-1
human macrophages.At all LEP concentrations, unhydrolyzed LEP significantly
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reduced IL-18 production ranging from 49.7% to 63.6%. On the other hand, only
0.25 mg/mL LEP-hydrolyzed treatment led to significant decrease in IL-18
production by 49.6%.

Effect of lunasin-enriched preparation did not affect the expression of
NLRP3 and ASC proteins involve in inflammasomes in THP-1 human
macrophages

Fig. 4.3 indicates that LEP treatment, whether unhydrolyzed or hydrolyzed, did
not affect expression of NLRP3 and ASC proteins involve in inflammasome.

Effect of lunasin-enriched preparation on production of intracellular
reactive oxygen species in THP-1 human macrophages

THP-1 macrophage like cells after treatment with LEP, LPS, and LPS + ATP
were incubated with 2’7’-dichlorofluoroscein diacetate, a non-fluorescent dye that
fluoresces after oxidation caused by ROSs(Owusu-Ansah, Yavari, & Banerjee,
2008). Images show increased fluorescence with LPS and LPS + ATP (Fig. 4.4)
compared to the control, as well as a significant decrease in fluorescence with
increased concentrations ofunhydrolyzed LEP. On the other hand, slight
reduction was observed in cells treated with hydrolyzed LEP. To confirm this
observation, quantitative fluorescent spectrophotometry and flow cytometry were
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conducted.At all concentrations used, unhydrolyzed LEP led to a significant
reduction in mean fluorescence intensity as compared to LPS + ATP-treated cells
(Fig. 4.5a). At 0.25 mg/mL unhydrolyzed LEP, the mean fluorescence intensity
was reduced from 723.25 (LPS + ATP) to 362.25 (LPS + ATP + 0.25 mg/mL
unhydrolyzed LEP) which is equivalent to 49.9%. On the other hand, hydrolyzed
LEP significantly reduced the production of intracellular ROS only at the highest
concentration used (0.25 mg/mL), by 30.9%. Fig. 4.5b shows the mean and
median fluorescence intensity from flow cytometry compared with the percentage
of stained cells in both unhydrolyzed and hydrolyzed LEP treatments, as well as
the histogram plots of the observed FITC-A fluorescence of the different
treatments. In both treatments, addition of LPS alone and LPS + ATP led to a
significant increase in the percentage of cells stained as well as mean and
median fluorescence intensities. In THP-1 cells treated with unhydrolyzed LEP,
the highest LEP concentration treatment at 0.25 mg/mL led to significant
reduction in the percentage of stained cells, mean fluorescence intensity and
median fluorescence intensity by 40.8%, 31.4% and 45.4%, respectively. On the
other hand, hydrolyzed LEP at 0.25 mg/mL only reduced the percentage of
stained cells and mean fluorescence intensity by 19.5% and 33.9%, respectively.
The observations from flow cytometry are in agreement with the fluorescence
microscopy and fluorescence spectrophotometry experiments. Representative
histograms for all treatments are also shown in Fig. 4.5. The right shift from the
treatment of LPS alone to the LPS + ATP treatment indicating the increased
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fluorescence was counteracted by addition of 0.25 mg/mL LEP, both hydrolyzed
and unhydrolyzed, in the LPS + ATP treatment.

Discussion

Inflammation is linked to multiple diseases, such as in neurodegenerative
disorders (Gao & Hong, 2008; Guo, Callaway, & Ting, 2015; Mao et al., 2017),
type II diabetes (Strowig, Henao-Mejia, Elinav, & Flavell, 2012), inflammatory
bowel disease (Peyrin-Biroulet, Lémann, 2011; Ruffolo et al., 2010), and cancer
(Balkwill & Mantovani, 2001; Mantovani, Allavena, Sica, & Balkwill, 2008; Simone
Reuter, 2011). Inflammation, and complications associated with it, account for
approximately 15% of cancer-related deaths (Mantovani et al., 2008). If chronic
inflammation can be inhibited without disruption of normal cell functions, this
could lead to breakthroughs in possible treatments and preventative measures
for these diseases. One possible mechanism for inhibiting chronic inflammation
is inhibiting the inflammasome, a multi-protein oligomer that is responsible for the
production of pro-inflammatory cytokines, and only activated under specific
conditions (Abais et al., 2015; Martinon, Burns, & Tschopp, 2002).
Lunasin has been reported to have anti-cancer and anti-inflammatory
properties (Hernández-Ledesma et al., 2009; Hsieh et al., 2017), and ROSs have
been linked to activation of the inflammasome (Abais et al., 2015; Guo et al.,
2015), but to our knowledge no studies have been done to determine if lunasin
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can inhibit the inflammasome by reduction of ROSs within the cell. This study
used lunasin-enriched preparation that was obtained by calcium chloride
precipitation (Price et al., 2016) to study its effect on inflammasome activation in
vitro using THP-1 human macrophages as well as LPS and ATP signals, known
initiators of inflammasome activation (Tschopp & Schroder, 2010).
Inflammasomes require a two-step process in order to activate, first is priming
with LPS which acts as an upstream regulator of NF-κB which transcribes pro-IL1β and NLRP3 (Ghonime et al., 2014), and then activation with ATP, which
releases ROS within the cell, which is critical for the binding sites of the NLRP3
to form a disulfide bond allowing oligomerization with ASC and pro-caspase-1 to
form the inflammasome (Abais et al., 2015; Bae & Park, 2011). ROSs have also
been shown to be crucial in the activation of active caspase-1 by oxidizing
thioredoxin (TRX), a redox protein, releasing thioredoxin-interacting protein
(TXNIP) which binds to the NLRP3 portion of the inflammasome and has been
proven to be a key step in activation (Abais et al., 2015; Zhou, Tardivel, Thorens,
Choi, & Tschopp, 2010). One of the most detrimental effects of this immune
response is the cascade of pro-inflammatory cytokines, which act as the priming
step like LPS, and the resulting cell and tissue death associated with sterile
inflammation (Rock, Latz, Ontiveros, & Kono, 2010). Cells treated with LEP
showed significant reduction in pro-inflammatory cytokine production expressed
into the supernatant, indicating there was an effect on the inflammasome
pathway, leading us to study the mechanism of action involved. Since there was
92

a reduction in cytokine expression, but NLRP3 and ASC were not affected by
LEP indicating a different mechanism of action.Our study showed the effect of
LEP in the production of intracellular ROS (Fig. 4.4 and 4.5) which could
potentially explain the observed reduction in the production of pro-inflammatory
cytokines IL-1β and IL-18 (Fig. 4.2). Previous studies have shown the ability of
lunasin to act as antioxidant leading to reduced inflammation(HernándezLedesma, Hsieh, & de Lumen, 2009). In addition, lunasin prevented galactoseinduced cataract formation in rats by attenuating oxidative damage through
upregulation of antioxidant enzymes (Dai et al,, 2016) and protected DNA by
suppressing generation of hydroxyl radical via blockage of the Fenton reaction
(Jeong, de Lumen & Jeong, 2010). Our current study supported these previous
studies showing the ability of LEP to reduce intracellular ROSs in THP-1 human
macrophages involved in inflammasome activation.
We also observed that pepsin-pancreatin hydrolysis led to lower ability of
LEP to reduce intracellular ROS in THP-1 human macrophages treated with LPS
and ATP. This may be attributed to reduction in amount of bioactive peptides
present in hydrolyzed LEP as our previous study showed reduction in the
concentrations of lunasin, Bowman-Birk inhibitor and Kunitz-type trypsin inhibitor
after pepsin-pancreatin hydrolysis (Price, Pangloli, Krishnan, & Dia, 2016). In the
previous study, more intact lunasin was associated with higher anti-proliferative
effects in colon cancer cells (Cruz-Huerta et al., 2015) and addition of BBI
complemented the anticancer effect of lunasin in xenograft model of breast
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cancer (Hsieh, Hernandez-Ledesma, Jeong, Park & de Lumen, 2010). This
indicated the importance of protecting lunasin from digestion to exert its potential
chemoprevetive effect. Fig. 4.6 shows the proposed mechanism that lunasin
uses to inhibit the production of pro-inflammatory cytokines IL-1ß and IL-18.
Since lunasin was able to reduce cytokine expression and intracellular ROSs, but
not inflammasome associated proteins, the two proposed mechanisms are
blocking ROSs from activating the inflammasome, and inhibiting activation of the
pro-interleukins.
In conclusion, lunasin-enriched products are able to inhibit inflammasome
activation in THP-1 human macrophages by reducing intracellular ROS,indicating
its potential use in aiding relief of chronic inflammation. Since the NLRP3 and
ASC proteins were not affected by LEP treatment in LPS+ATP inflammasomeactivated THP-1 human macrophages, further studies are needed to determine
the exact mechanism lunasin uses to inhibit inflammasome.

94

References Cited

Abais, J. M., Xia, M., Zhang, Y., Boini, K. M., & Li, P.-L. (2015). Redox regulation
of NLRP3 inflammasomes: ROS as trigger or effector? Antioxidants & Redox
Signaling, 22(13), 1111–29. http://doi.org/10.1089/ars.2014.5994
Bae, J. Y., & Park, H. H. (2011). Crystal structure of NALP3 Protein Pyrin
Domain (PYD) and its implications in inflammasome assembly. Journal of
Biological Chemistry, 286(45), 39528–39536.
http://doi.org/10.1074/jbc.M111.278812
Balkwill, F., & Mantovani, A. (2001). Inflammation and cancer: Back to Virchow?
Lancet, 357(9255), 539–545. http://doi.org/10.1016/S0140-6736(00)040460.
Cam, A., & de Mejia, E. G. (2012). RGD-peptide lunasin inhibits Akt-mediated
NF-κB activation in human macrophages through interaction with the αVβ3
integrin. Molecular Nutrition & Food Research, 56(10), 1569–81.
http://doi.org/10.1002/mnfr.201200301
Cruz-Huerta, E., Fernández-Tomé, S., Arques, M. C., Amigo, L., Recio, I.,
Clemente, A., & Hernández-Ledesma, B. (2015). The protective role of the
Bowman-Birk protease inhibitor in soybean lunasin digestion: the effect of
released peptides on colon cancer growth. Food Funct., 6(8), 2626–2635.
http://doi.org/10.1039/C5FO00454C
Dai Guangzhi, Ping Zhang, Pei Ye, Miaoqing Zhang, Ning Han, H. S. and S. T.
95

(2016). The Chemopreventive Peptide Lunasin Inhibits d-GalactoseInduced Experimental Cataract in Rats. Protein & Peptide Letters.
Dia, V. P., & Mejia, E. G. de. (2010). Lunasin promotes apoptosis in human colon
cancer cells by mitochondrial pathway activation and induction of nuclear
clusterin expression. Cancer Letters, 295(1), 44–53.
http://doi.org/10.1016/j.canlet.2010.02.010
Gao, H. M., & Hong, J. S. (2008). Why neurodegenerative diseases are
progressive: uncontrolled inflammation drives disease progression. Trends
in Immunology, 29(8), 357–365. http://doi.org/10.1016/j.it.2008.05.002
Ghonime, M. G., Shamaa, O. R., Das, S., Eldomany, R. A., Fernandes-Alnemri,
T., Alnemri, E. S., … Wewers, M. D. (2014). Inflammasome priming by
lipopolysaccharide is dependent upon ERK signaling and proteasome
function. Journal of Immunology (Baltimore, Md. : 1950), 192(8), 3881–8.
http://doi.org/10.4049/jimmunol.1301974
Guo, H., Callaway, J. B., & Ting, J. P.-Y. (2015). Inflammasomes: mechanism of
action, role in disease, and therapeutics. Nature Medicine, 21(7), 677–687.
http://doi.org/10.1038/nm.3893
Haneklaus, M., O’Neill, L. A. J., & Coll, R. C. (2013). Modulatory mechanisms
controlling the NLRP3 inflammasome in inflammation: Recent
developments. Current Opinion in Immunology, 25(1), 40–45.
http://doi.org/10.1016/j.coi.2012.12.004
Hernández-Ledesma, B., Hsieh, C.-C., & de Lumen, B. O. (2009). Antioxidant
96

and anti-inflammatory properties of cancer preventive peptide lunasin in
RAW 264.7 macrophages. Biochemical and Biophysical Research
Communications, 390(3), 803–8. http://doi.org/10.1016/j.bbrc.2009.10.053
Hsieh, C.-C., Chou, M.-J., & Wang, C.-H. (2017). Lunasin attenuates obesityrelated inflammation in RAW264.7 cells and 3T3-L1 adipocytes by inhibiting
inflammatory cytokine production. PloS One, 12(2), e0171969.
http://doi.org/10.1371/journal.pone.0171969
Hsieh, C.-C., Hernández-Ledesma, B., Jeong, H. J., Park, J. H., & de Lumen, B.
O. (2010). Complementary roles in cancer prevention: protease inhibitor
makes the cancer preventive peptide lunasin bioavailable. PloS One, 5(1),
e8890. http://doi.org/10.1371/journal.pone.0008890
Jeong, J. B., De Lumen, B. O., & Jeong, H. J. (2010). Lunasin peptide purified
from Solanum nigrum L. protects DNA from oxidative damage by
suppressing the generation of hydroxyl radical via blocking fenton reaction.
Cancer Letters, 293(1), 58–64. http://doi.org/10.1016/j.canlet.2009.12.019
Kulp, A., & Kuehn, M. J. (2012). Biological Functions and Biogenesis of Secreted
Bacterial Outer Membrane Vesicles. Annu Rev Microbiol., 163–184.
http://doi.org/10.1146/annurev.micro.091208.073413.Biological
Lu, Y. C., Yeh, W. C., & Ohashi, P. S. (2008). LPS/TLR4 signal transduction
pathway. Cytokine, 42(2), 145–151. http://doi.org/10.1016/j.cyto.2008.01.006
Lule, V. K., Garg, S., Pophaly, S. D., Hitesh, & Tomar, S. K. (2015). “Potential
health benefits of lunasin: A multifaceted soy-derived bioactive peptide.”
97

Journal of Food Science, 80(3), C485–C494. http://doi.org/10.1111/17503841.12786
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related
inflammation. Nature, 454(7203), 436–444.
http://doi.org/10.1038/nature07205
Mao, Z., Liu, C., Ji, S., Yang, Q., Ye, H., Han, H., & Xue, Z. (2017). The NLRP3
Inflammasome is Involved in the Pathogenesis of Parkinson’s Disease in
Rats. Neurochemical Research, 0(0), 0. http://doi.org/10.1007/s11064-0172185-0
Martinon, F., Burns, K., & Tschopp, J. (2002). The Inflammasome: A molecular
platform triggering activation of inflammatory caspases and processing of
proIL-β. Molecular Cell, 10(2), 417–426. http://doi.org/10.1016/S10972765(02)00599-3
Montoya-Rodríguez, A., de Mejía, E. G., Dia, V. P., Reyes-Moreno, C., & MilánCarrillo, J. (2014). Extrusion improved the anti-inflammatory effect of
amaranth (Amaranthus hypochondriacus) hydrolysates in LPS-induced
human THP-1 macrophage-like and mouse RAW 264.7 macrophages by
preventing activation of NF-??B signaling. Molecular Nutrition and Food
Research, 58(5), 1028–1041. http://doi.org/10.1002/mnfr.201300764
Owusu-Ansah, E., Yavari, A., & Banerjee, U. (2008). A protocol for in vivo
detection of reactive oxygen species. Nature Protocol, 1–9.
http://doi.org/10.1038/nprot.2008.23
98

Peyrin-Biroulet, Lémann, M. (2011). Review article: Remission rates achievable
by current therapies for inflammatory bowel disease. Alimentary
Pharmacology and Therapeutics, 33(8), 870–879.
http://doi.org/10.1111/j.1365-2036.2011.04599.x
Price, S. J., Pangloli, P., Krishnan, H. B., & Dia, V. P. (2016). Kunitz trypsin
inhibitor in addition to Bowman-Birk inhibitor influence stability of lunasin
against pepsin-pancreatin hydrolysis. Food Research International, 90, 205–
215. http://doi.org/10.1016/j.foodres.2016.10.051
Rock, K. L., Latz, E., Ontiveros, F., & Kono, H. (2010). The sterile inflammatory
response. Annual Review of Immunology, 28(3), 321–42.
http://doi.org/10.1146/annurev-immunol-030409-101311
Rubartelli, A., & Lotze, M. T. (2007). Inside, outside, upside down: damageassociated molecular-pattern molecules (DAMPs) and redox. Trends in
Immunology, 28(10), 429–436. http://doi.org/10.1016/j.it.2007.08.004
Ruffolo, C., Scarpa, M., Faggian, D., Basso, D., D’Incà, R., Plebani, M., …
Angriman, I. (2010). Subclinical intestinal inflammation in patients with
Crohn’s disease following bowel resection: a smoldering fire. Journal of
Gastrointestinal Surgery : Official Journal of the Society for Surgery of the
Alimentary Tract, 14(1), 24–31. http://doi.org/10.1007/s11605-009-1070-9
Shidal, C., Al-Rayyan, N., Yaddanapudi, K., & Davis, K. R. (2016). Lunasin is a
novel therapeutic agent for targeting melanoma cancer stem cells.
Oncotarget, 7(51), 84128–84141. http://doi.org/10.18632/oncotarget.11554
99

Simone Reuter, B. B. A. (2011). Oxidative stress, inflammation, and cancer: How
are they linked? Free Radic Biol Med, 49(11), 1603–1616.
http://doi.org/10.1016/j.freeradbiomed.2010.09.006.Oxidative
Strowig, T., Henao-Mejia, J., Elinav, E., & Flavell, R. (2012). Inflammasomes in
health and disease. Nature, 481(7381), 278–286.
http://doi.org/10.1038/nature10759
Tőzsér, J., & Benko, S. (2016). Natural Compounds as Regulators of NLRP3
Inflammasome-Mediated IL-1β Production. Mediators of Inflammation, 2016.
http://doi.org/10.1155/2016/5460302
Tschopp, J., & Schroder, K. (2010). NLRP3 inflammasome activation: The
convergence of multiple signalling pathways on ROS production? Nat Rev
Immunol, 10(3), 210–215. http://doi.org/10.1038/nri2725
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010). Thioredoxininteracting protein links oxidative stress to inflammasome activation. Nat
Immunol, 11(2), 136–140. http://doi.org/10.1038/ni.1831

100

Appendix
Figures
Fig. 4.1. Protein profile of lunasin-enriched material prepared by calcium
chloride precipitation methods. Figure 4.1a shows size-exclusion
chromatography of CaCl2 lunasin-enriched product, chromatogram overlays
hydrolyzed (blue) and unhydrolyzed (red) samples. Unhydrolyzed sample
contains large peak associated with high molecular weight compounds which
were reduced after pepsin-pancreatin hydrolysis. Figure 4.1b shows highperformance liquid chromatography results of hydrolyzed sample (red),
unhydrolyzed (green), and lunasin standard (blue). Results show a reduction of
peaks in hydrolyzed sample, correlating to reduction of peptides during
hydrolysis.
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Fig. 4.1. continued
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Fig. 4.2. Lunasin-enriched preparation reduced the production of IL-1β and
IL-18 in THP-1 human macrophages treated with LPS and ATP for
inflammasome activation. Figure 4.2a shows an overall reduction of IL-1β
expression in LEP treated cells compared to the positive control of the LPS +
ATP treated cells. Bars with different letter(s) are significantly different from each
other (P<0.05). Figure 4.2b shows the reduction in IL-18 secretion by THP-1
human macrophages when treated with LEP. Bars with different letters were
significantly different from each other (P<0.05, n = 6).
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Fig. 4.2. continued
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Fig. 4.3. Lunasin-enriched preparation did not affect the expression of
NLRP3 and ASC proteins involved in the formation of inflammasome
macromolecular complex in THP-1 human macrophages.
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Fig. 4.4. Lunasin-enriched preparation reduced production of intracellular
reactive oxygen species as measured by fluorescence microscopy.
Unhydrolyzed LEP (a) is more effective in lowering ROS production than
hydrolyzed LEP (b).
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Fig. 4.4. continued
a) Unhydrolyzed

b) Hydrolyzed
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Fig. 4.5. Measurement of intracellular ROS in THP-1 macrophages by
fluorescence spectroscopy and flow cytometry shows that lunasinenriched treatment reduced intracellular reactive oxygen species
production in THP-1 human macrophages treated with LPS and ATP. a)
Mean values of fluorescence spectroscopy indicate intracellular ROS was
produced after treatment with LPS and ATP, with all values differing significantly
from the negative control. The highest concentration of hydrolyzed and
unhydrolyzed LEP treatment (0.25mg) differ significantly from LPS + ATP
treatment. The three concentrations of unhydrolyzed LEP differ significantly from
both LPS and LPS + ATP treatment, but the two lower concentrations of
hydrolyzed LEP did not significantly reduce ROS compared to the LPS and LPS
+ ATP treatments. b) Mean and median fluorescence intensity of flow cytometry
compared with percentage of cells that were stained. Highest concentration of
hydrolyzed and unhydrolyzed LEP treated cells differ significantly from LPS and
LPS + ATP treated cells. Flow cytometry histogram shows a decrease in FITC-A
corresponding to LEP treatment concentrations. Means with different letter(s) are
significantly different from each other (P<0.05, n = 4).
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Fig. 4.5. continued
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Fig. 4.6. Proposed mechanism by which lunasin-enriched preparation (LEP)
inhibit activation of inflammasomes in THP-1 human macrophages by LPS
and ATP. Treatment of LPS and ATP lead to increase production of intracellular
reactive oxygen species (ROS) which is capable of promoting oligomerization of
NLRP3 and ASC components of inflammasome. This oligomer will then bind to
pro-caspase-1 resulting in processing and activation of pro-caspase-1 to
caspase-1. Active caspase-1 is responsible for the maturation of proinflammatory cytokines IL-1β and IL-18 which are responsible for chronic
inflammation. LEP treatment (

) led to reduced production of these pro-

inflammatory cytokines by reducing the amount of intracellular ROS induced by
LPS and ATP treatment.
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Fig. 4.6. continued
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CHAPTER V
CONCLUSIONS
Production of lunasin-enriched materials was accomplished by both calcium
chloride and pH precipitation methods. Bowman-Birk and Kunitz-Trypsin inhibitor
played an important role in stabilizing lunasin against pepsin-pancreatin
hydrolysis, and the use of KTI-mutant soybean study proved that KTI played a
critical role in the stabilization of lunasin. Treatment of THP-1 human
macrophagesprimed and activated by LPS and ATP for inflammasome activation
with lunasin-enriched material led to reduction of intracellular reactive oxygen
species which resulted in reduced pro-inflammatory cytokines. This research is
the first to report the following:
•

Importance of Kunitz trypsin inhibitor in the stability of lunasin against
pepsin-pancreatin hydrolysis; and

•

Ability of lunasin-enriched material to inhibit activation of
inflammasomes in vitro

Determination of the exact component present in lunasin-enriched material
responsible for the inhibition of inflammasomes is warranted. In addition, other
mechanism of action involved in the inhibition of the inflammasomes must be
studied. An in vivo study would be beneficial in determining if lunasin has the
potential to be used as a chemopreventive agent against inflammation
associated diseases.
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